<p>摩根士丹利的分析师 Craig Hettenbach 对 Hims &amp; Hers Health 维持持有评级，目标价为 21.00 美元。</p>
<h3>在 TipRanks 上享受 55% 的折扣</h3>
<ul>
<li>解锁对冲基金级别的数据和强大的投资工具，以做出更聪明、更精准的决策</li>
<li>发现表现优异的股票投资理念，并升级为市场领先者的投资组合，使用智能投资者精选</li>
</ul>
<p>Craig Hettenbach 维持持有评级是基于与 Hims &amp; Hers Health 的增长战略和盈利能力相关的多种因素。管理层积极追求收入扩张，甚至提高了长期销售预期，但这伴随着 EBITDA 指引的下调和毛利率的显著下降，显示出盈利压力和对投资者耐心的需求。</p>
<p>与此同时，公司首次出现 EBITDA 未达预期的情况，第一季度业绩未能达到市场预期，近期 EBITDA 指引低于共识，尽管顶线目标更强。虽然国际表现和重新合作的 Novo 伙伴关系令人鼓舞，但 Hettenbach 认为，股票的上涨空间受到限制，直到有更明确的可持续毛利改善和积极的 EBITDA 修正的证据，这支持了持有评级和不变的 21 美元目标价。</p>
<p>在今天发布的另一份报告中，花旗也对该股票给予了持有评级，目标价为 28.00 美元。</p>

HIMS

2 倍做多 HIMS ETF - Defiance

医疗业 ETF - SPDR

HIMY

医疗业 ETF - Vanguard

标普全球医疗股指数 ETF - iShares

美国医疗保健供应商 ETF - iShares

标普医疗保健服务 ETF - SPDR

<p>摩根士丹利的分析师 Craig Hettenbach 对 Hims & Hers Health 维持了持有评级，并重申了 21.00 美元的目标价。该决定基于公司积极的收入扩张努力，但伴随着 EBITDA 指引的下调和毛利率的下降，显示出盈利压力。尽管公司在收入方面表现强劲，但未能达到首次 EBITDA 预期。花旗也给予持有评级，目标价为 28.00 美元，反映出对可持续利润改善和正向 EBITDA 修订的担忧</p>

<p>Analyst Craig Hettenbach of Morgan Stanley maintained a Hold rating on Hims &amp; Hers Health, retaining the price target of $21.00.</p>
<div class="lb-trans"><p>摩根士丹利的分析师 Craig Hettenbach 对 Hims &amp; Hers Health 维持持有评级，目标价为 21.00 美元。</p>
</div><h3>Claim 55% Off TipRanks</h3>
<div class="lb-trans"><h3>在 TipRanks 上享受 55% 的折扣</h3>
</div><ul>
<li>Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions</li>
<li>Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks</li>
</ul>
<div class="lb-trans"><ul>
<li>解锁对冲基金级别的数据和强大的投资工具，以做出更聪明、更精准的决策</li>
<li>发现表现优异的股票投资理念，并升级为市场领先者的投资组合，使用智能投资者精选</li>
</ul>
</div><p>Craig Hettenbach has given his Hold rating due to a combination of factors related to Hims &amp; Hers Health’s growth strategy and profitability profile. Management is aggressively pursuing revenue expansion and even raised its longer-term sales outlook, yet this comes alongside reduced EBITDA guidance and a notable decline in gross margins, signaling profitability pressure and the need for investor patience.</p>
<div class="lb-trans"><p>Craig Hettenbach 维持持有评级是基于与 Hims &amp; Hers Health 的增长战略和盈利能力相关的多种因素。管理层积极追求收入扩张，甚至提高了长期销售预期，但这伴随着 EBITDA 指引的下调和毛利率的显著下降，显示出盈利压力和对投资者耐心的需求。</p>
</div><p>At the same time, the company delivered its first EBITDA miss, with Q1 results falling short of Street expectations and near-term EBITDA guidance sitting below consensus despite stronger top-line targets. While international performance and the renewed Novo partnership are encouraging, Hettenbach believes the stock’s upside is constrained until there is clearer evidence of sustainable margin improvement and positive EBITDA revisions, supporting a Hold rating and an unchanged $21 price target.</p>
<div class="lb-trans"><p>与此同时，公司首次出现 EBITDA 未达预期的情况，第一季度业绩未能达到市场预期，近期 EBITDA 指引低于共识，尽管顶线目标更强。虽然国际表现和重新合作的 Novo 伙伴关系令人鼓舞，但 Hettenbach 认为，股票的上涨空间受到限制，直到有更明确的可持续毛利改善和积极的 EBITDA 修正的证据，这支持了持有评级和不变的 21 美元目标价。</p>
</div><p>In another report released today, Citi also assigned a Hold rating to the stock with a $28.00 price target.</p>
<div class="lb-trans"><p>在今天发布的另一份报告中，花旗也对该股票给予了持有评级，目标价为 28.00 美元。</p>
</div>

Hims & Hers Health: Hold Maintained as Profitability Pressures Offset Growth; $21 Price Target Reiterated

Tip Ranks

Hims & Hers Health

Defiance Leveraged Long +Income HIMS ETF

摩根士丹利

花旗

MORGAN STANLEY DEP SHS EA REP 1/1000 SHS NON CUM PFD O

MORGAN STANLEY DEP SHS REPSTG 1/1000TH PFD SER Q

MORGAN STANLEY DEP SHS REPS 1/1000 7.125% PFD E

MORGAN STANLEY NON-CUM DEP SH REP 1/1000 PFD SER I

MORGAN STANLEY 4.875 DEP SHS REP 1/1000 NCUM PFD SR L

MORGAN STANLEY 6.5%DEP SHS REPSTG 1/1000 NON CUM SER P

MORGAN STANLEY DEP SHS REPS 1/1000 PFD SER 'A'

MORGAN STANLEY DEP SHS REPR 1/1000TH INT PFD SER 'F' FX

MORGAN STANLEY DEP SHS REP 1/1000 NON-CUM PFD STK SER K

CITIGROUP INC 6.250 NON CUM SER II PFD WI

Hims & Hers Health：由于盈利压力抵消了增长，维持持有评级；目标价仍为 21 美元